Table S1. Summary of protocol treatment (FAS).
| Summary of protocol treatment | Docetaxel + bevacizumab (N=49) | Pemetrexed + bevacizumab (N=50) | P value |
|---|---|---|---|
| Number of cycles (cytotoxic agents), median [range] | 5.0 [1–25] | 7.5 [1–28] | 0.129 |
| Relative dose intensity (cytotoxic agents), median [range] (%) | 82.0 [62–100] | 94.0 [76–100] | 0.001 |
| Number of cycles (bevacizumab), median [range] | 5.0 [1–25] | 6.0 [1–26] | 0.311 |
| Relative dose intensity (bevacizumab), median [range] (%) | 98.0 [66–100] | 96.5 [56–100] | 0.768 |
| Number (%) of events leading delay of treatment | 12 (24.5) | 21 (42.0) | 0.065 |
| Number (%) of events leading dose modification of chemotherapy | 32 (65.3) | 9 (18.0) | <0.001 |
| Number (%) of events leading to discontinuation of all treatments | 10 (20.4) | 6 (12.0) | 0.256 |
| Number (%) of events leading to discontinuation of bevacizumab | 9 (18.4) | 4 (8.0) | 0.127 |
| Number (%) of events leading to discontinuation of docetaxel or pemetrexed | 15 (30.6) | 8 (16.0) | 0.085 |
| Number (%) of treatment-related deaths | 0 | 1 (2.0) | 0.320 |
FAS, full analysis set.